Kezar Life Sciences Key Executives
This section highlights Kezar Life Sciences's key executives, including their titles and compensation details.
Find Contacts at Kezar Life Sciences
(Showing 0 of )
Kezar Life Sciences Earnings
This section highlights Kezar Life Sciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
$4.70
Stock Price
$34.34M
Market Cap
55
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Kezar Life Sciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $7.00M | $- | $- | $- |
| Cost of Revenue | $- | $1.07M | $1.02M | $1.51M | $1.54M |
| Gross Profit | $- | $5.93M | $-1.02M | $-1.51M | $-1.54M |
| Gross Profit Ratio | 0.00% | 84.77% | - | - | - |
| Research and Development Expenses | $65.74M | $85.70M | $51.01M | $38.94M | $30.98M |
| General and Administrative Expenses | $23.39M | $26.54M | $20.15M | $15.72M | $11.97M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $23.39M | $26.54M | $20.15M | $15.72M | $11.97M |
| Other Expenses | $1.47M | $6.19M | $- | $- | $- |
| Operating Expenses | $90.61M | $118.42M | $71.16M | $54.66M | $42.95M |
| Cost and Expenses | $- | $112.24M | $71.16M | $54.66M | $42.95M |
| Interest Income | $8.46M | $11.10M | $4.11M | $188.00K | $1.21M |
| Interest Expense | $-1.59M | $1.55M | $1.19M | $159.00K | $- |
| Depreciation and Amortization | $-5.28M | $1.07M | $1.02M | $1.51M | $1.54M |
| EBITDA | $-90.61M | $-99.25M | $-66.11M | $-52.96M | $-40.26M |
| EBITDA Ratio | - | -1417.91% | - | - | - |
| Operating Income | $-90.61M | $-105.24M | $-71.16M | $-54.66M | $-42.95M |
| Operating Income Ratio | - | -1503.39% | - | - | - |
| Total Other Income Expenses Net | $6.87M | $3.37M | $2.92M | $29.00K | $1.21M |
| Income Before Tax | $-83.74M | $-101.87M | $-68.24M | $-54.63M | $-41.74M |
| Income Before Tax Ratio | - | -1455.29% | - | - | - |
| Income Tax Expense | $- | $- | $-2.92M | $-1.35M | $-2.75M |
| Net Income | $-83.74M | $-101.87M | $-65.32M | $-53.28M | $-38.99M |
| Net Income Ratio | - | -1455.29% | - | - | - |
| EPS | $-1.15 | $-1.40 | $-0.97 | $-1.01 | $-0.89 |
| EPS Diluted | $-1.15 | $-1.40 | $-0.97 | $-1.01 | $-0.89 |
| Weighted Average Shares Outstanding | 72.90M | 72.55M | 67.37M | 52.76M | 44.00M |
| Weighted Average Shares Outstanding Diluted | 72.90M | 72.55M | 67.37M | 52.76M | 44.00M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $-5.43M | $7.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $261.00K | $260.00K | $280.00K | $278.00K | $249.00K | $259.00K | $13.00M | $458.00K | $431.00K | $417.00K | $387.00K | $378.00K | $373.00K | $372.00K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-261.00K | $-260.00K | $-5.71M | $6.72M | $-249.00K | $-259.00K | $-13.00M | $-458.00K | $-431.00K | $-417.00K | $-387.00K | $-378.00K | $-373.00K | $-372.00K | $- | $- | $- | $- |
| Gross Profit Ratio | - | 0.00% | - | - | 105.16% | 96.03% | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $16.03M | $16.24M | $16.30M | $17.17M | $22.64M | $23.74M | $21.00M | $18.32M | $4.86M | $13.86M | $11.35M | $10.94M | $9.78M | $10.53M | $9.34M | $9.29M | $8.12M | $8.26M | $7.15M | $7.46M |
| General and Administrative Expenses | $5.54M | $5.71M | $5.60M | $6.54M | $5.76M | $8.79M | $5.79M | $6.21M | $5.17M | $5.07M | $4.98M | $4.93M | $4.32M | $3.97M | $3.67M | $3.76M | $2.95M | $3.29M | $2.71M | $3.02M |
| Selling and Marketing Expenses | $- | $- | $-261.00K | $-260.00K | $-280.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.54M | $5.71M | $5.34M | $6.28M | $5.48M | $8.79M | $5.79M | $6.21M | $5.17M | $5.07M | $4.98M | $4.93M | $4.32M | $3.97M | $3.67M | $3.76M | $2.95M | $3.29M | $2.71M | $3.02M |
| Other Expenses | $-12.00K | $- | $1.48M | $- | $6.19M | $- | $- | $- | $10.00M | $- | $- | $- | $1.00K | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $21.56M | $21.95M | $21.64M | $23.45M | $28.12M | $32.53M | $26.78M | $24.52M | $20.03M | $18.93M | $16.32M | $15.88M | $14.10M | $14.50M | $13.01M | $13.05M | $11.07M | $11.55M | $9.85M | $10.48M |
| Cost and Expenses | $21.56M | $21.95M | $23.38M | $23.71M | $28.40M | $32.53M | $26.78M | $24.52M | $20.03M | $18.93M | $16.32M | $15.88M | $14.10M | $14.50M | $13.01M | $13.05M | $11.07M | $11.55M | $9.85M | $10.48M |
| Interest Income | $1.73M | $2.04M | $2.24M | $2.45M | $2.73M | $2.82M | $2.86M | $2.69M | $2.20M | $1.39M | $408.00K | $108.00K | $50.00K | $37.00K | $47.00K | $54.00K | $127.00K | $262.00K | $353.00K | $466.00K |
| Interest Expense | $389.00K | $403.00K | $401.00K | $400.00K | $399.00K | $396.00K | $385.00K | $370.00K | $349.00K | $310.00K | $272.00K | $254.00K | $159.00K | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $259.00K | $260.00K | $261.00K | $260.00K | $280.00K | $278.00K | $249.00K | $259.00K | $-283.00K | $458.00K | $431.00K | $417.00K | $387.00K | $378.00K | $373.00K | $372.00K | $368.00K | $445.00K | $369.00K | $362.00K |
| EBITDA | $-19.57M | $-19.65M | $-20.89M | $-21.00M | $-31.58M | $-22.43M | $-23.67M | $-21.65M | $-17.83M | $-17.08M | $-15.48M | $-15.43M | $-13.40M | $-14.12M | $-12.59M | $-12.62M | $-10.70M | $-11.11M | $-9.48M | $-10.12M |
| EBITDA Ratio | - | - | - | - | 581.82% | -320.41% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-21.56M | $-21.95M | $-23.38M | $-23.71M | $-28.40M | $-25.53M | $-26.78M | $-24.52M | $-20.03M | $-18.93M | $-16.32M | $-15.88M | $-14.10M | $-14.50M | $-13.01M | $-13.05M | $-11.07M | $-11.55M | $-9.85M | $-10.48M |
| Operating Income Ratio | - | - | - | - | 523.25% | -364.67% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $1.34M | $1.64M | $1.84M | $2.05M | $-3.86M | $2.42M | $2.48M | $2.33M | $1.85M | $1.08M | $136.00K | $-146.00K | $-109.00K | $37.00K | $47.00K | $54.00K | $127.00K | $262.00K | $353.00K | $466.00K |
| Income Before Tax | $-20.22M | $-20.31M | $-21.55M | $-21.66M | $-32.26M | $-23.10M | $-24.31M | $-22.20M | $-18.18M | $-17.85M | $-16.19M | $-16.02M | $-14.21M | $-14.46M | $-12.96M | $-12.99M | $-10.94M | $-11.29M | $-9.50M | $-10.01M |
| Income Before Tax Ratio | - | - | - | - | 594.33% | -330.04% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $216.72K | $-628.00K | $-278.00K | $2.86M | $-1.96M | $-1.85M | $-1.08M | $408.00K | $146.00K | $-337.00K | $-108.00K | $- | $- | $-368.00K | $- | $-369.00K | $- |
| Net Income | $-20.22M | $-20.31M | $-21.55M | $-21.66M | $-32.26M | $-23.10M | $-24.31M | $-20.24M | $-16.33M | $-16.77M | $-16.19M | $-16.17M | $-14.21M | $-14.46M | $-12.96M | $-12.99M | $-10.94M | $-11.29M | $-9.50M | $-10.01M |
| Net Income Ratio | - | - | - | - | 594.33% | -330.04% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-2.77 | $-0.28 | $-2.96 | $-0.30 | $-0.44 | $-0.32 | $-0.34 | $-0.28 | $-0.23 | $-0.23 | $-0.25 | $-0.27 | $-0.25 | $-0.28 | $-0.25 | $-0.25 | $-0.22 | $-0.23 | $-0.22 | $-0.20 |
| EPS Diluted | $-2.77 | $-0.28 | $-2.96 | $-0.30 | $-0.44 | $-0.32 | $-0.34 | $-0.28 | $-0.23 | $-0.23 | $-0.25 | $-0.27 | $-0.25 | $-0.28 | $-0.25 | $-0.25 | $-0.22 | $-0.23 | $-0.22 | $-0.20 |
| Weighted Average Shares Outstanding | 7.30M | 72.96M | 7.28M | 72.80M | 72.74M | 72.68M | 72.46M | 72.33M | 72.23M | 72.15M | 64.28M | 60.63M | 55.98M | 52.05M | 51.90M | 51.06M | 50.08M | 50.00M | 42.94M | 51.06M |
| Weighted Average Shares Outstanding Diluted | 7.30M | 72.96M | 7.28M | 72.80M | 72.74M | 72.68M | 72.46M | 72.33M | 72.23M | 72.15M | 64.28M | 60.63M | 55.98M | 52.05M | 51.90M | 51.06M | 50.08M | 50.00M | 42.94M | 51.06M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $41.75M | $35.49M | $40.46M | $62.88M | $21.23M |
| Short Term Investments | $90.50M | $165.88M | $236.10M | $145.47M | $119.22M |
| Cash and Short Term Investments | $132.25M | $201.37M | $276.56M | $208.35M | $140.45M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $2.50M | $1.97M |
| Other Current Assets | $5.24M | $5.58M | $9.16M | $3.30M | $4.36M |
| Total Current Assets | $137.49M | $206.95M | $285.72M | $211.65M | $144.81M |
| Property Plant Equipment Net | $4.78M | $8.69M | $13.17M | $6.00M | $6.75M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.42M | $5.59M | $674.00K | $282.00K | $282.00K |
| Total Non-Current Assets | $7.19M | $14.29M | $13.85M | $6.28M | $7.03M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $144.68M | $221.24M | $299.57M | $217.93M | $151.84M |
| Account Payables | $3.65M | $8.25M | $2.48M | $2.03M | $2.36M |
| Short Term Debt | $12.27M | $3.01M | $5.13M | $2.40M | $2.08M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $-3.53M | $- | $- | $- | $3.02M |
| Other Current Liabilities | $4.41M | $6.48M | $3.39M | $3.79M | $2.00M |
| Total Current Liabilities | $20.33M | $17.74M | $11.00M | $8.21M | $6.44M |
| Long Term Debt | $2.33M | $15.92M | $18.70M | $12.85M | $8.84M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $5.11M | $- | $- | $- | $-4.42M |
| Total Non-Current Liabilities | $7.44M | $15.92M | $18.70M | $12.85M | $4.42M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $27.77M | $33.66M | $29.70M | $21.06M | $10.86M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $7.00K | $73.00K | $68.00K | $56.00K | $46.00K |
| Retained Earnings | $-434.50M | $-350.76M | $-248.89M | $-180.65M | $-126.02M |
| Accumulated Other Comprehensive Income Loss | $-162.00K | $-130.00K | $-923.00K | $-291.00K | $-137.00K |
| Other Total Stockholders Equity | $551.57M | $538.39M | $519.62M | $377.76M | $267.09M |
| Total Stockholders Equity | $116.92M | $187.57M | $269.87M | $196.88M | $140.98M |
| Total Equity | $116.92M | $187.57M | $269.87M | $196.88M | $140.98M |
| Total Liabilities and Stockholders Equity | $144.68M | $221.24M | $299.57M | $217.93M | $151.84M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $144.68M | $221.24M | $299.57M | $217.93M | $151.84M |
| Total Investments | $90.50M | $165.88M | $236.10M | $145.47M | $119.22M |
| Total Debt | $11.07M | $18.93M | $21.26M | $14.04M | $5.46M |
| Net Debt | $-30.68M | $-16.56M | $-19.19M | $-48.84M | $-15.76M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $41.75M | $34.86M | $28.28M | $33.03M | $35.49M | $26.50M | $28.11M | $36.13M | $40.46M | $64.45M | $105.39M | $38.91M | $62.88M | $57.09M | $26.38M | $22.91M | $21.23M | $12.83M | $17.30M | $20.57M |
| Short Term Investments | $90.50M | $113.53M | $135.91M | $146.77M | $165.88M | $191.71M | $208.48M | $221.54M | $236.10M | $225.93M | $201.45M | $203.70M | $145.47M | $63.66M | $102.59M | $119.40M | $119.22M | $137.12M | $140.18M | $102.78M |
| Cash and Short Term Investments | $132.25M | $148.39M | $164.18M | $179.80M | $201.37M | $218.21M | $236.59M | $257.67M | $276.56M | $290.38M | $306.84M | $242.61M | $208.35M | $120.76M | $128.97M | $142.31M | $140.45M | $149.95M | $157.47M | $123.35M |
| Net Receivables | $938.00K | $1.69M | $1.69M | $4.08M | $- | $7.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $4.38M | $- | $- | $- | $- | $- | $- | $2.50M | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $4.30M | $6.30M | $983.00K | $1.74M | $5.58M | $5.31M | $6.92M | $7.56M | $9.16M | $8.54M | $4.49M | $3.39M | $3.30M | $3.99M | $4.37M | $3.37M | $4.36M | $3.86M | $3.09M | $3.18M |
| Total Current Assets | $137.49M | $156.38M | $167.62M | $185.61M | $206.95M | $230.52M | $243.50M | $265.23M | $285.72M | $298.93M | $311.33M | $246.00M | $211.65M | $124.75M | $133.35M | $145.68M | $144.81M | $153.81M | $160.56M | $126.53M |
| Property Plant Equipment Net | $4.78M | $5.29M | $5.78M | $8.02M | $8.69M | $12.47M | $13.31M | $13.86M | $13.17M | $5.56M | $5.89M | $5.59M | $6.00M | $5.85M | $6.04M | $6.38M | $6.75M | $7.12M | $7.48M | $7.83M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $145.47M | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.42M | $2.42M | $6.52M | $5.50M | $5.59M | $6.33M | $6.56M | $5.09M | $674.00K | $282.00K | $282.00K | $282.00K | $-145.19M | $282.00K | $282.00K | $282.00K | $282.00K | $282.00K | $282.00K | $282.00K |
| Total Non-Current Assets | $7.19M | $7.71M | $12.30M | $13.52M | $14.29M | $18.81M | $19.88M | $18.95M | $13.85M | $5.84M | $6.17M | $5.87M | $6.28M | $6.14M | $6.33M | $6.66M | $7.03M | $7.40M | $7.76M | $8.11M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $144.68M | $164.09M | $179.92M | $199.13M | $221.24M | $249.33M | $263.38M | $284.18M | $299.57M | $304.77M | $317.50M | $251.87M | $217.93M | $130.89M | $139.67M | $152.34M | $151.84M | $161.21M | $168.32M | $134.64M |
| Account Payables | $3.65M | $3.46M | $2.26M | $5.06M | $8.25M | $3.12M | $2.49M | $4.14M | $2.48M | $2.27M | $1.92M | $1.36M | $2.03M | $1.54M | $1.63M | $3.58M | $2.36M | $1.28M | $1.01M | $1.58M |
| Short Term Debt | $8.74M | $7.30M | $9.13M | $4.44M | $6.02M | $5.79M | $5.56M | $5.34M | $2.56M | $2.66M | $2.57M | $2.48M | $1.20M | $2.32M | $2.24M | $2.16M | $1.04M | $1.00M | $1.94M | $1.87M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $2.43M | $- | $1 | $- | $- | $- | $- | $- | $-1.28M | $- | $9.62M | $- | $3.19M | $2.89M | $3.02M | $3.87M | $3.03M | $4.20M |
| Other Current Liabilities | $7.93M | $9.66M | $6.10M | $6.66M | $3.47M | $7.76M | $5.68M | $4.16M | $5.95M | $4.66M | $3.36M | $3.14M | $4.99M | $4.01M | $2.08M | $1.82M | $3.04M | $3.90M | $2.10M | $3.32M |
| Total Current Liabilities | $20.33M | $20.43M | $17.50M | $16.16M | $17.74M | $16.67M | $13.74M | $13.64M | $11.00M | $9.60M | $7.85M | $6.98M | $8.21M | $7.87M | $5.94M | $7.56M | $6.44M | $6.19M | $5.04M | $6.77M |
| Long Term Debt | $7.44M | $9.61M | $11.74M | $13.85M | $15.92M | $23.31M | $24.78M | $26.20M | $18.70M | $11.99M | $14.84M | $15.47M | $12.85M | $7.07M | $7.68M | $8.28M | $4.42M | $9.39M | $9.92M | $10.44M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $-6.65M | $-7.41M | $-8.15M | $- | $- | $-2.56M | $-2.90M | $- | $-3.54M | $-3.84M | $-4.14M | $- | $-4.69M | $-4.96M | $-5.22M |
| Total Non-Current Liabilities | $7.44M | $9.61M | $11.74M | $13.85M | $15.92M | $16.66M | $17.36M | $18.05M | $18.70M | $11.99M | $12.29M | $12.57M | $12.85M | $3.54M | $3.84M | $4.14M | $4.42M | $4.69M | $4.96M | $5.22M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $27.77M | $30.04M | $29.24M | $30.01M | $33.66M | $33.33M | $31.10M | $31.69M | $29.70M | $21.58M | $20.14M | $19.55M | $21.06M | $11.41M | $9.79M | $11.70M | $10.86M | $10.89M | $10.01M | $11.99M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $7.00K | $7.00K | $73.00K | $73.00K | $73.00K | $73.00K | $73.00K | $71.00K | $68.00K | $68.00K | $68.00K | $60.00K | $56.00K | $49.00K | $48.00K | $48.00K | $46.00K | $46.00K | $46.00K | $38.00K |
| Retained Earnings | $-434.50M | $-414.28M | $-393.97M | $-372.42M | $-350.76M | $-318.50M | $-295.40M | $-271.09M | $-248.89M | $-230.71M | $-212.87M | $-196.68M | $-180.65M | $-166.44M | $-151.98M | $-139.02M | $-126.02M | $-115.08M | $-103.79M | $-94.29M |
| Accumulated Other Comprehensive Income Loss | $-162.00K | $107.00K | $-385.00K | $-355.00K | $-130.00K | $-687.00K | $-830.00K | $-523.00K | $-923.00K | $-1.47M | $-1.16M | $-782.00K | $-291.00K | $-195.00K | $-155.00K | $-140.00K | $-137.00K | $-112.00K | $25.00K | $-122.00K |
| Other Total Stockholders Equity | $551.57M | $548.22M | $544.97M | $541.82M | $538.39M | $535.11M | $528.43M | $524.03M | $519.62M | $515.30M | $511.32M | $429.71M | $377.76M | $286.07M | $281.97M | $279.75M | $267.09M | $265.47M | $262.04M | $217.03M |
| Total Stockholders Equity | $116.92M | $134.05M | $150.69M | $169.12M | $187.57M | $215.99M | $232.28M | $252.49M | $269.87M | $283.19M | $297.36M | $232.31M | $196.88M | $119.48M | $129.89M | $140.64M | $140.98M | $150.32M | $158.32M | $122.65M |
| Total Equity | $116.92M | $134.05M | $150.69M | $169.12M | $187.57M | $215.99M | $232.28M | $252.49M | $269.87M | $283.19M | $297.36M | $232.31M | $196.88M | $119.48M | $129.89M | $140.64M | $140.98M | $150.32M | $158.32M | $122.65M |
| Total Liabilities and Stockholders Equity | $144.68M | $164.09M | $179.92M | $199.13M | $221.24M | $249.33M | $263.38M | $284.18M | $299.57M | $304.77M | $317.50M | $251.87M | $217.93M | $130.89M | $139.67M | $152.34M | $151.84M | $161.21M | $168.32M | $134.64M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $144.68M | $164.09M | $179.92M | $199.13M | $221.24M | $249.33M | $263.38M | $284.18M | $299.57M | $304.77M | $317.50M | $251.87M | $217.93M | $130.89M | $139.67M | $152.34M | $151.84M | $161.21M | $168.32M | $134.64M |
| Total Investments | $90.50M | $113.53M | $135.91M | $146.77M | $165.88M | $191.71M | $208.48M | $221.54M | $236.10M | $225.93M | $201.45M | $203.70M | $290.95M | $63.66M | $102.59M | $119.40M | $119.22M | $137.12M | $140.18M | $102.78M |
| Total Debt | $16.18M | $16.91M | $17.61M | $18.29M | $18.93M | $19.55M | $20.15M | $20.72M | $21.26M | $13.32M | $13.57M | $13.81M | $14.04M | $4.69M | $4.96M | $5.22M | $5.46M | $5.70M | $5.93M | $6.15M |
| Net Debt | $-25.57M | $-17.95M | $-10.67M | $-14.75M | $-16.56M | $-6.94M | $-7.96M | $-15.41M | $-19.19M | $-51.14M | $-91.82M | $-25.09M | $-48.84M | $-52.40M | $-21.42M | $-17.69M | $-15.76M | $-7.13M | $-11.37M | $-14.42M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-83.74M | $-101.87M | $-68.24M | $-54.63M | $-41.74M |
| Depreciation and Amortization | $-4.00M | $1.07M | $1.02M | $1.51M | $1.54M |
| Deferred Income Tax | $- | $- | $- | $1.77M | $- |
| Stock Based Compensation | $13.01M | $18.14M | $14.01M | $7.60M | $4.94M |
| Change in Working Capital | $-1.30M | $4.71M | $-4.46M | $1.23M | $-2.01M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $6.35M | $1.81M | $1.22M | $313.00K |
| Other Working Capital | $-1.30M | $-1.64M | $-6.27M | $9.00K | $-2.32M |
| Other Non Cash Items | $1.82M | $-3.68M | $-1.18M | $91.00K | $317.00K |
| Net Cash Provided by Operating Activities | $-74.21M | $-81.64M | $-58.85M | $-42.44M | $-36.95M |
| Investments in Property Plant and Equipment | $-29.00K | $-1.81M | $-1.58M | $-316.00K | $-194.00K |
| Acquisitions Net | $- | $- | $89.81K | $28.13K | $56.30K |
| Purchases of Investments | $-91.34M | $-180.40M | $-332.20M | $-156.38M | $-225.73M |
| Sales Maturities of Investments | $171.79M | $258.25M | $242.39M | $128.25M | $169.42M |
| Other Investing Activities | $- | $5.00K | $-89.81K | $-28.13K | $-56.30K |
| Net Cash Used for Investing Activities | $80.43M | $76.05M | $-91.39M | $-28.44M | $-56.50M |
| Debt Repayment | $- | $- | $- | $9.53M | $- |
| Common Stock Issued | $103.00K | $638.00K | $126.54M | $100.97M | $99.19M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $103.00K | $638.00K | $1.32M | $2.08M | $456.00K |
| Net Cash Used Provided by Financing Activities | $103.00K | $638.00K | $127.86M | $112.58M | $99.64M |
| Effect of Forex Changes on Cash | $-63.00K | $-2.00K | $-49.00K | $-50.00K | $82.00K |
| Net Change in Cash | $6.26M | $-4.96M | $-22.43M | $41.65M | $6.28M |
| Cash at End of Period | $41.75M | $35.49M | $40.46M | $62.88M | $21.23M |
| Cash at Beginning of Period | $35.49M | $40.46M | $62.88M | $21.23M | $14.95M |
| Operating Cash Flow | $-74.21M | $-81.64M | $-58.85M | $-42.44M | $-36.95M |
| Capital Expenditure | $-29.00K | $-1.81M | $-1.58M | $-316.00K | $-194.00K |
| Free Cash Flow | $-74.24M | $-83.45M | $-60.42M | $-42.75M | $-37.14M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-20.22M | $-20.31M | $-21.55M | $-21.66M | $-32.26M | $-23.10M | $-24.31M | $-22.20M | $-18.18M | $-17.85M | $-16.19M | $-16.02M | $-14.21M | $-14.46M | $-12.96M | $-12.99M | $-10.94M | $-11.29M | $-9.50M | $-10.01M |
| Depreciation and Amortization | $259.00K | $-3.87M | $261.00K | $260.00K | $280.00K | $278.00K | $249.00K | $259.00K | $-283.00K | $458.00K | $431.00K | $417.00K | $387.00K | $378.00K | $373.00K | $372.00K | $368.00K | $445.00K | $369.00K | $362.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-2.82M | $-1.76M | $-1.82M | $- | $- | $- | $- | $339.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $3.31M | $3.19M | $3.08M | $3.43M | $3.22M | $6.63M | $4.02M | $4.26M | $3.82M | $3.79M | $3.30M | $3.10M | $1.85M | $1.88M | $1.94M | $1.93M | $1.28M | $1.27M | $1.22M | $1.17M |
| Change in Working Capital | $668.00K | $2.50M | $945.00K | $-3.45M | $8.35M | $-2.31M | $199.00K | $-1.53M | $58.00K | $-2.19M | $-1.13M | $-1.20M | $483.00K | $1.84M | $-2.92M | $1.82M | $-422.00K | $231.00K | $-2.09M | $272.00K |
| Accounts Receivables | $- | $- | $- | $- | $7.00M | $-7.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $1.50M | $-97.00K | $-3.01M | $959.00K | $2.94M | $1.10M | $1.35M | $2.37M | $2.17M | $274.00K | $-834.00K | $60.00K | $1.73M | $-1.66M | $1.09M | $306.00K | $1.23M | $-1.96M | $739.00K |
| Other Working Capital | $668.00K | $1.00M | $1.04M | $-440.00K | $7.39M | $-5.24M | $-901.00K | $-2.88M | $-2.32M | $-4.36M | $-1.40M | $-369.00K | $423.00K | $111.00K | $-1.26M | $735.00K | $-728.00K | $-995.00K | $-134.00K | $-467.00K |
| Other Non Cash Items | $-841.00K | $998.00K | $225.00K | $5.51M | $4.26M | $58.00K | $59.00K | $-1.65M | $-1.29M | $-572.00K | $53.00K | $53.00K | $408.00K | $408.00K | $531.00K | $514.00K | $408.00K | $92.00K | $-87.00K | $-96.00K |
| Net Cash Provided by Operating Activities | $-16.82M | $-17.49M | $-17.03M | $-22.86M | $-18.98M | $-20.20M | $-21.60M | $-20.86M | $-15.88M | $-16.36M | $-13.29M | $-13.31M | $-11.08M | $-9.95M | $-13.04M | $-8.36M | $-9.31M | $-9.25M | $-10.09M | $-8.30M |
| Investments in Property Plant and Equipment | $-11.00K | $-18.00K | $- | $- | $-1.00K | $-136.00K | $-1.38M | $-297.00K | $-343.00K | $-603.00K | $-182.00K | $-450.00K | $-266.00K | $-26.00K | $-24.00K | $- | $-84.00K | $- | $-17.00K | $-93.00K |
| Acquisitions Net | $- | $- | $- | $- | $26.27K | $5.00K | $-14.58K | $-16.69K | $8.32K | $24.11K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-19.23M | $-19.98M | $-34.78M | $-17.34M | $-49.87M | $-35.30M | $-41.17M | $-54.06M | $-93.57M | $-96.56M | $-67.56M | $-74.52M | $-113.22M | $-5.24M | $-11.73M | $-26.19M | $-43.06M | $-38.89M | $-71.26M | $-72.52M |
| Sales Maturities of Investments | $42.99M | $44.05M | $47.00M | $37.75M | $77.75M | $54.00M | $55.75M | $70.75M | $85.25M | $72.45M | $69.25M | $15.44M | $31.00M | $43.75M | $28.00M | $25.50M | $60.46M | $41.68M | $34.00M | $33.28M |
| Other Investing Activities | $- | $- | $- | $20.41M | $27.88M | $18.71M | $14.58K | $16.69K | $-8.32K | $-24.11K | $1.69M | $-59.08M | $-82.22M | $38.51M | $16.27M | $-687.00K | $17.40M | $2.79M | $-37.26M | $-39.24M |
| Net Cash Used for Investing Activities | $23.74M | $24.06M | $12.22M | $20.41M | $27.88M | $18.57M | $13.20M | $16.39M | $-8.66M | $-24.71M | $1.51M | $-59.53M | $-82.49M | $38.48M | $16.25M | $-687.00K | $17.32M | $2.79M | $-37.28M | $-39.33M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-56.00K | $- | $56.00K | $- | $59.00K | $43.00K | $382.00K | $154.00K | $-813.00K | $185.00K | $78.32M | $48.85M | $89.83M | $2.21M | $282.00K | $10.73M | $317.00K | $1.96M | $43.99M | $53.37M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $103.00K | $- | $- | $- | $638.00K | $- | $- | $- | $1.32M | $- | $- | $- | $9.53M | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $47.00K | $- | $56.00K | $- | $59.00K | $43.00K | $382.00K | $154.00K | $506.00K | $185.00K | $78.32M | $48.85M | $99.36M | $2.21M | $282.00K | $10.73M | $317.00K | $1.96M | $43.99M | $53.37M |
| Effect of Forex Changes on Cash | $-75.00K | $16.00K | $3.00K | $-7.00K | $38.00K | $-23.00K | $-5.00K | $-12.00K | $41.00K | $-51.00K | $-64.00K | $25.00K | $4.00K | $-30.00K | $-13.00K | $-11.00K | $67.00K | $35.00K | $97.00K | $-117.00K |
| Net Change in Cash | $6.89M | $6.58M | $-4.76M | $-2.46M | $8.99M | $-1.61M | $-8.02M | $-4.33M | $-24.00M | $-40.93M | $66.48M | $-23.97M | $5.79M | $30.71M | $3.47M | $1.68M | $8.39M | $-4.46M | $-3.27M | $5.62M |
| Cash at End of Period | $41.75M | $34.86M | $28.28M | $33.03M | $35.49M | $26.50M | $28.11M | $36.13M | $40.46M | $64.45M | $105.39M | $38.91M | $62.88M | $57.09M | $26.38M | $22.91M | $21.23M | $12.83M | $17.30M | $20.57M |
| Cash at Beginning of Period | $34.86M | $28.28M | $33.03M | $35.49M | $26.50M | $28.11M | $36.13M | $40.46M | $64.45M | $105.39M | $38.91M | $62.88M | $57.09M | $26.38M | $22.91M | $21.23M | $12.83M | $17.30M | $20.57M | $14.95M |
| Operating Cash Flow | $-16.82M | $-17.49M | $-17.03M | $-22.86M | $-18.98M | $-20.20M | $-21.60M | $-20.86M | $-15.88M | $-16.36M | $-13.29M | $-13.31M | $-11.08M | $-9.95M | $-13.04M | $-8.36M | $-9.31M | $-9.25M | $-10.09M | $-8.30M |
| Capital Expenditure | $-11.00K | $-18.00K | $- | $- | $-1.00K | $-136.00K | $-1.38M | $-297.00K | $-343.00K | $-603.00K | $-182.00K | $-450.00K | $-266.00K | $-26.00K | $-24.00K | $- | $-84.00K | $- | $-17.00K | $-93.00K |
| Free Cash Flow | $-16.84M | $-17.51M | $-17.03M | $-22.86M | $-18.98M | $-20.34M | $-22.98M | $-21.16M | $-16.23M | $-16.96M | $-13.47M | $-13.76M | $-11.35M | $-9.98M | $-13.07M | $-8.36M | $-9.39M | $-9.25M | $-10.11M | $-8.39M |
Kezar Life Sciences Dividends
Explore Kezar Life Sciences's dividend history, including dividend yield, payout ratio, and historical payments.
Kezar Life Sciences News
Read the latest news about Kezar Life Sciences, including recent articles, headlines, and updates.
Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)
Kezar Life Sciences, Inc. (NASDAQ:KZR ) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ET Company Participants Chris Kirk - Chief Executive Officer & Co-Founder Dr. Craig Lammert - Principal Investigator of PORTOLA Study Gideon Hirschfield - Professor University of Toronto, Autoimmune Liver Disease Research Conference Call Participants Matt Phipps - William Blair Divya Rao - TD Cowen Maury Raycroft - Jefferies Derek Archila - Wells Fargo Mitchell Kapoor - H.C. Wainwright Operator Good day, everyone.
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported positive topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH) and reported fourth quarter and year end 2024 financial results. “.
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET. The event will highlight topline data from Kezar's PORTOLA tri.
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “The team at Kezar has made great progress towards completing the double-blind portion of the PORTOLA trial as we prepare for a data release in first half of 2025,”.
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors' and officers' possible violations of state laws. If you own Kezar Life Sciences stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY.
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on October 29, 2024 (the “Effective Time”). The Co.
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the “Board”) has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC (“Concentra”) to acquire all of the outstanding shares of common stock of Kezar for cash consideration o.
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced key clinical development updates. The IDMC overseeing the PORTOLA Phase 2a clinical trial of zetomipzomib in patients with AIH recommended that the trial may proceed without modification following its third scheduled meeting. The IDMC examined safety data from a.
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it has received an unsolicited, non-binding proposal from Concentra Biosciences, LLC (“Concentra”), a Delaware limited liability company, to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per s.
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference with the U.S. Food and Drug Administration (FDA) that the zetomipzomib Investigational New Drug (IND) application for the treatment of lupus nephritis (LN) has been placed on clinical hold. This action follows Kezar's communication t.
Kezar Life Sciences halts mid-stage trial for lupus treatment
Kezar Life Sciences said on Monday it was stopping enrollment of new patients and dosing of ongoing patients in its mid-stage study for treating a symptom of lupus, following the recommendation of an independent committee after four deaths.
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced the voluntary cessation in enrollment of new patients and dosing of ongoing patients in the Phase 2b PALIZADE clinical trial, pending further evaluation. PALIZADE is a global, placebo-controlled, randomized, double-blind Phase 2b clinical trial evaluating the efficacy and.
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 72,000 shares of its common stock with an exercise price of $0.55 per share, which is equal to the closing price of Kezar'.
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 12:30 pm ET in New York, NY. A webcast of the panel discussion will be available.
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar.
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
A constellation of stocks beckons daring investors from the great expanse of the financial galaxy, where stars glitter with promise and fortunes wait to be discovered. The first stop on the journey is a celestial body whose excellent recovery rates and record-breaking throughput suggest a gold mine of opportunities.
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. "The efforts over the past year by the team at Kezar have put us in a strong position as we advance our promising, first-in-class immunology and oncology programs," said Ch.
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
SHANGHAI & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved Kezar's investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN). Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
NEW YORK , Dec. 4, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kezar Life Sciences, Inc. (NASDAQ: KZR) on behalf of the company's shareholders. The investigation seeks to determine whether Kezar Life Sciences's directors breached their fiduciary duties in connection with recent corporate actions that have caused a decline in Kezar Life Sciences's stock price.
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 1:20 pm ET in Miami, FL. A webcast from the fireside chat will be available on the “Events &.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for KZR.